Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Po-Yueh Chen

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
The Lancet. Gastroenterology & Hepatology|December 22, 2022
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trialJyh-Ming Liou, Xiao-Tao Jiang, Chieh-Chang Chen, et al.
Lancet (London, England)|October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
Clinical and Molecular Hepatology|July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosisChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Gut|January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairmentChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International|March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in TaiwanChen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Hepatology International|January 26, 2023
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in TaiwanChen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, et al.
Nature Communications|July 9, 2025
Clinical impact of pharmacogenetic risk variants in a large chinese cohortChun-Yu Wei, Ming-Shien Wen, Chih-Kuang Cheng, et al.
Nature|October 15, 2025
Population-specific polygenic risk scores for people of Han Chinese ancestryHung-Hsin Chen, Chien-Hsiun Chen, Ming-Chih Hou, et al.
Nature|October 15, 2025
The Taiwan Precision Medicine Initiative provides a cohort for large-scale studiesHsin-Chou Yang, Pui-Yan Kwok, Ling-Hui Li, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
The Lancet. Gastroenterology & Hepatology|December 22, 2022
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trialJyh-Ming Liou, Xiao-Tao Jiang, Chieh-Chang Chen, et al.
Lancet (London, England)|October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
Clinical and Molecular Hepatology|July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosisChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Gut|January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairmentChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International|March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in TaiwanChen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Hepatology International|January 26, 2023
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in TaiwanChen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, et al.
Nature Communications|July 9, 2025
Clinical impact of pharmacogenetic risk variants in a large chinese cohortChun-Yu Wei, Ming-Shien Wen, Chih-Kuang Cheng, et al.
Nature|October 15, 2025
Population-specific polygenic risk scores for people of Han Chinese ancestryHung-Hsin Chen, Chien-Hsiun Chen, Ming-Chih Hou, et al.
Nature|October 15, 2025
The Taiwan Precision Medicine Initiative provides a cohort for large-scale studiesHsin-Chou Yang, Pui-Yan Kwok, Ling-Hui Li, et al.
Pageof 5